Vatalanib (PTK 787/ZK 222584) GLEEVEC
Target and mechanism of action: this is a small molecule that binds to tyrosine kinase of receptors VEGF and platelet growth factor (platelet-derived growth factor or PDGF) blocking the function and consequently inhibit the formation of new blood vessels in the tumor.
Indications: the drug is corrently being studied in cancers of the colon and rectum, in combination with chemotherapy.
Mode of administration: it is administered orally as tablets.
Most common side effects: asthenia, diarrhea, nausea, dizziness, headache, hypertension.
Trade name: it is currently still under study and is not marketed in any country (pharmaceutical companies Novartis and Schering AG).